Brady Bohrmann - Profile and Investment Details
Find investors who align with your industry, stage, and vision. Unlock Brady Bohrmann’s full investment profile, including location, investment focus, portfolio companies, and preferences. Sign up today and start building investor relationships that fuel your startup’s growth.
Get connected with all investors today
- Advertising,
- Health Care,
- Data Integration,
- Hospitals,
- Semantic Search,
- Sports,
- Messaging,
- Women Founded,
- Enterprise Software,
- Career Planning,
- Intelligent Systems,
- Content Management Systems (CMS),
- Ad Targeting,
- Artificial Intelligence (AI),
- Personal Finance,
- Tech,
- Information Technology (IT),
- Marketplace,
- Internet of Things (IoT),
- Software,
- Biotechnology,
- Productivity Software,
- FinTech,
- Consumer Internet,
- Marketing,
- Health Diagnostics,
- Social Impact,
- Digital Health,
- Medical,
- SaaS,
- Therapeutics,
- Machine Learning,
- Pharmaceuticals
Social media:
Past investments:
- Talla
- NanoNets
- Node
- Enlibrium
- Figg
- Seva
- Shelby.tv
- Tapad
- Silarus Therapeutics
- Memrise
- Ankasa Regenerative Therapeutics
- BookBub
- Averon
- Empyr
- Avelas Biosciences
- Fortis Therapeutics
- Awarepoint
- BotChain
- LoopIt
- AlphaSheets
- ScoreStream
- AristaMD
- Skycatch
- Simulmedia
- Conjur
- Primer
- Backupify
- Piper Networks
- MOGL
- AeroFS
- Selectable Media
- Cheezburger
- Indix
- Chartio
- Sitari Pharmaceuticals
- Orion Labs
- Janux Therapeutics
- Joy
- Calporta Therapeutics
- Happy Cloud
- Cloudant
- Redbooth
- Cardeas Pharma
- Thyritope Biosciences
- Smyte
- Cadherx Therapeutics
- Byliner
- Nanigans
- Pando
- StackRox
- Quippi
- Pingup
- Sidecar Technologies
- Proximal Data
- Jnana
- Kinvey
- Otonomy
- Synthorx
- Vook
- StackIQ
- Kaltura
Investor Profile
Brady Bohrmann is a Venture Capital based in Portland, Maine, United States with a diverse investment portfolio that includes companies such as Talla, NanoNets, Node, Enlibrium, Figg, Seva, Shelby.tv, Tapad, Silarus Therapeutics, Memrise, Ankasa Regenerative Therapeutics, BookBub, Averon, Empyr, Avelas Biosciences, Fortis Therapeutics, AwarepointBotChain, LoopIt, AlphaSheets, ScoreStream, AristaMD, Skycatch, Simulmedia, Conjur, Primer, Backupify, Piper Networks, MOGL, AeroFS, Selectable Media, Cheezburger, Indix, Chartio, Sitari Pharmaceuticals, Orion Labs, Janux Therapeutics, Joy, Calporta Therapeutics, Happy Cloud, Cloudant, Redbooth, Cardeas Pharma, Thyritope Biosciences, Smyte, Cadherx Therapeutics, Byliner, Nanigans, Pando, StackRox, Quippi, Pingup, Sidecar Technologies, Proximal Data, Jnana, Kinvey, Otonomy, Synthorx, Vook, StackIQ, Kaltura, . Over time, Brady Bohrmann has demonstrated experience in supporting a range of businesses across various sectors.
While it is not publicly confirmed whether Brady Bohrmann is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.
Startups and entrepreneurs operating in sectors related to Advertising, Health Care, Data Integration, Hospitals, Semantic Search, Sports, Messaging, Women Founded, Enterprise Software, Career Planning, Intelligent Systems, Content Management Systems (CMS), Ad Targeting, Artificial Intelligence (AI), Personal Finance, Tech, Information Technology (IT), Marketplace, Internet of Things (IoT), Software, Biotechnology, Productivity Software, FinTech, Consumer Internet, Marketing, Health Diagnostics, Social Impact, Digital Health, Medical, SaaS, Therapeutics, Machine Learning, Pharmaceuticals may find it worthwhile to explore potential connections with Brady Bohrmann, as their portfolio suggests a familiarity and interest in this area.
Understanding Brady Bohrmann’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.
Angel Match is the easiest way to research investors for your startup so you can spend less time Googling and more time raising.
Find the perfect investors today
